Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ImmuCell Corporation (ICCC : NSDQ)

• Company Description    ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea. Number of Employees: 75

• Price / Volume Information    Yesterday's Closing Price: $6.10 Daily Weekly Monthly 20 Day Moving Average: 19,333 shares Shares Outstanding: 9.05 (millions) Market Capitalization: $55.18 (millions) Beta: 0.29 52 Week High: $7.60 52 Week Low: $3.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.29% -12.64% 12 Week -0.05% -4.19% Year To Date 18.45% 3.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 56 EVERGREEN DR - PORTLAND,ME 04103 USA ph: 207-878-2770 fax: 207-878-2117 iccc@lythampartners.com http://www.immucell.com

• General Corporate Information    Officers Michael F. Brigham - Chief Executive Officer; President; Principal Fina Bobbi Jo Brockmann - Vice President of Sales and Marketing and Director Bryan K. Gathagan - Director Steven T. Rosgen - Director David S. Tomsche - Director Peer Information ImmuCell Corporation (BJCT) ImmuCell Corporation (CADMQ) ImmuCell Corporation (APNO) ImmuCell Corporation (UPDC) ImmuCell Corporation (IMTIQ) ImmuCell Corporation (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 452525306 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 9.05 Most Recent Split Date: 7.00 (0.01:1) Beta: 0.29 Market Capitalization: $55.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 32.10 PEG Ratio: - Price Ratios Price/Book: 1.85 Price/Cash Flow: 94.87 Price / Sales: 1.95 EPS Growth vs. Year Ago Period: 130.00% vs. Previous Quarter: -62.50% Sales Growth vs. Year Ago Period: 17.76% vs. Previous Quarter: -20.11% ROE 09/30/25 - - 06/30/25 - 6.25 03/31/25 - -1.02 ROA 09/30/25 - - 06/30/25 - 3.87 03/31/25 - -0.61 Current Ratio 09/30/25 - - 06/30/25 - 3.85 03/31/25 - 4.12 Quick Ratio 09/30/25 - - 06/30/25 - 1.99 03/31/25 - 2.21 Operating Margin 09/30/25 - - 06/30/25 - 6.23 03/31/25 - -1.00 Net Margin 09/30/25 - - 06/30/25 - 6.23 03/31/25 - -1.00 Pre-Tax Margin 09/30/25 - - 06/30/25 - 6.27 03/31/25 - -0.96 Book Value 09/30/25 - - 06/30/25 - 3.30 03/31/25 - 3.22 Inventory Turnover 09/30/25 - - 06/30/25 - 2.34 03/31/25 - 2.50 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.28 03/31/25 - 0.30 Debt-to-Capital 09/30/25 - - 06/30/25 - 21.67 03/31/25 - 22.99

Powered by Zacks Investment Research ©